These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 9493595

  • 1. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP, Peyrou V, Savi P, Bernat A, Herbert JM.
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [Abstract] [Full Text] [Related]

  • 2. SR 121787, a new orally active fibrinogen receptor antagonist.
    Savi P, Badorc A, Lalé A, Bordes MF, Bornia J, Labouret C, Bernat A, de Cointet P, Hoffmann P, Maffrand JP, Herbert JM.
    Thromb Haemost; 1998 Sep; 80(3):469-76. PubMed ID: 9759629
    [Abstract] [Full Text] [Related]

  • 3. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells.
    Herbert JM, Savi P, Jeske WP, Walenga JM.
    Thromb Haemost; 1998 Aug; 80(2):326-31. PubMed ID: 9716161
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of microsurgical thrombosis by the platelet glycoprotein IIb/IIIa antagonist SR121566A.
    Ching S, Thoma A, Monkman S, Kelton JG.
    Plast Reconstr Surg; 2003 Jul; 112(1):177-85. PubMed ID: 12832891
    [Abstract] [Full Text] [Related]

  • 5. Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat.
    Hérault JP, Dol F, Gaich C, Bernat A, Herbert JM.
    Thromb Haemost; 1999 Jun; 81(6):957-60. PubMed ID: 10404775
    [Abstract] [Full Text] [Related]

  • 6. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
    Hoffmann P, Bernat A, Savi P, Herbert JM.
    J Pharmacol Exp Ther; 1998 Aug; 286(2):670-5. PubMed ID: 9694919
    [Abstract] [Full Text] [Related]

  • 7. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M, Tomasiak M, Rusak T, Winnicka K, Dobrzycki S.
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [Abstract] [Full Text] [Related]

  • 8. A laboratory method for parallel determination of platelet aggregation and thrombin generation.
    Köstenberger M, Gallistl S, Cvirn G, Muntean W.
    Clin Lab; 2004 Sep; 50(1-2):41-8. PubMed ID: 15000219
    [Abstract] [Full Text] [Related]

  • 9. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
    Hoffmann P, Bernat A, Savi P, Herbert JM.
    J Cardiovasc Pharmacol; 1997 Sep; 30(3):360-6. PubMed ID: 9300321
    [Abstract] [Full Text] [Related]

  • 10. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S.
    Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
    [Abstract] [Full Text] [Related]

  • 11. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
    Savi P, Bernat A, Lalé A, Roque C, Zamboni G, Herbert JM.
    Platelets; 2000 Feb; 11(1):43-8. PubMed ID: 10938881
    [Abstract] [Full Text] [Related]

  • 12. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A, Bordes MF, de Cointet P, Savi P, Bernat A, Lalé A, Petitou M, Maffrand JP, Herbert JM.
    J Med Chem; 1997 Oct 10; 40(21):3393-401. PubMed ID: 9341914
    [Abstract] [Full Text] [Related]

  • 13. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Müller TH.
    J Cardiovasc Pharmacol; 1997 Aug 10; 30(2):261-72. PubMed ID: 9269956
    [Abstract] [Full Text] [Related]

  • 14. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J.
    J Lab Clin Med; 2000 Mar 10; 135(3):247-55. PubMed ID: 10711863
    [Abstract] [Full Text] [Related]

  • 15. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters.
    Klinkhardt U, Kirchmaier CM, Westrup D, Breddin HK, Mahnel R, Graff J, Hild M, Harder S.
    Thromb Res; 2000 Feb 15; 97(4):201-7. PubMed ID: 10674406
    [Abstract] [Full Text] [Related]

  • 16. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
    Rand ML, Packham MA, Taylor DM, Yeo EL, Gemmell CH, Patil S, Lam SC.
    Thromb Haemost; 1999 Dec 15; 82(6):1680-6. PubMed ID: 10613655
    [Abstract] [Full Text] [Related]

  • 17. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S, Kawasaki T, Hisamichi N, Sakai Y, Taniuchi Y, Inagaki O, Yano S, Suzuki K, Terazaki C, Masuho Y, Satoh N, Takenaka T, Yanagi K, Ohshima N.
    Thromb Haemost; 1996 Apr 15; 75(4):679-84. PubMed ID: 8743199
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications.
    Haas S, Walenga JM, Jeske WP, Fareed J.
    Semin Thromb Hemost; 1999 Apr 15; 25 Suppl 1():67-75. PubMed ID: 10357155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.